Tango Therapeutics, Inc. (TNGX) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$38.7M

EPS$-0.87

Market Cap$2.9B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Malte Peters

CEO & Executive Director

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Founded: 2014
Employees: 137
Headquarters

⚡

Core Efficiency

ROE?

-11.19%

ROA?

-9.72%

D/E Ratio?

0.15

📊

Profitability Ratios

Current Ratio?

16.32

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 9, 2026 (in 122 days)

Annual Report (10-K) — Based on filing pattern

Aug 9, 2026

Predicted10-K

Mar 5, 2026

10-KQ4 20257d after period end

Mar 5, 2026

10-KFY 202564d after period end

Nov 4, 2025

10-QQ3 20257d after period end

Aug 5, 2025

10-QQ2 20257d after period end

May 12, 2025

10-QQ1 20257d after period end

Feb 27, 2025

10-KQ4 20248d after period end

Feb 27, 2025

10-KFY 202558d after period end

Nov 6, 2024

10-QQ3 20245d after period end

Loading company sections...

Tango Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness